Bridging the Gaps in Lung Cancer: 6 Month Update Winter Lung Cancer Conference 2025 - Episode 12

Tailoring Immunotherapy Strategies for Advanced NSCLC

,

Panelists discuss how treatment decisions for advanced non–small cell lung cancer (NSCLC) without actionable mutations depend on factors like PD-L1 status, histology (eg, squamous [SQ]), and biomarkers like STK11/KEAP1. Chemotherapy may be added based on individual patient factors, with promising advancements expected in 2025.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Expert Insights on Recent Advancements in LS-SCLC
    EP. 2: Key Updates in the Treatment of ES-SCLC
    EP. 3: Expert Perspectives on Tarlatamab in ES-SCLC
    EP. 4: Looking Ahead in SCLC: ADCs and Other Novel Agents
    EP. 5: Shifting Paradigms With Perioperative Treatment Strategies in Early-Stage NSCLC
    EP. 6: Personalizing Adjuvant Targeted Therapy in Early-Stage NSCLC
    EP. 7: New Targeted Approaches in Unresectable Early-Stage NSCL
    EP. 8: Navigating New Treatment Options in the Frontline Management of Advanced EGFR-Mutant NSCLC
    EP. 9: Expert Insights for Treatment Sequencing in EGFR-Mutant Advanced NSCLC in the Second Line and Beyond
    EP. 10: Latest Advances in the Management of Advanced NSCLC with ALK or ROS1 Mutations
    EP. 11: Recent Updates in the Management Advanced NSCLC with HER2 or NRG1 Alterations
    Now Viewing
    EP. 12: Tailoring Immunotherapy Strategies for Advanced NSCLC

    Video content above is prompted by the following:

    • How do you select between mono immunotherapy (IO) and dual IO therapy in patients with advanced NSCLC and no actionable mutations?
    • In which patients do you consider the addition of chemotherapy?
    • How does PD-L1 status influence your decision?
    • What is your preferred management strategy for patients with SQ histology? STK11 or KEAP1? What data influence your treatment approach?
    • What advancements in lung cancer from 2024 will have the most significant impact on your clinical practice in 2025?
    • What do you see as the greatest treatment gaps and unmet needs in the management of advanced NSCLC, and what are the most promising opportunities for future advancements?
    x